May 13, 2020 / 11:48 AM / 24 days ago

BRIEF-Capricor Reports Positive Results From Study In Duchenne Muscular Dystrophy Patients Treated With Cap-1002

May 13 (Reuters) - Capricor Therapeutics Inc:

* CAPRICOR ANNOUNCES POSITIVE TOP-LINE FINAL RESULTS FROM HOPE-2 STUDY IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY TREATED WITH LEAD CANDIDATE CAP-1002

* CAPRICOR THERAPEUTICS INC - PLANNING TO MEET WITH FDA TO DISCUSS PATHWAY TO APPROVAL

* CAPRICOR THERAPEUTICS INC - DATA SHOWED IMPROVEMENTS IN UPPER LIMB, CARDIAC AND RESPIRATORY FUNCTION

* CAPRICOR THERAPEUTICS INC - CAP-1002 WAS GENERALLY SAFE AND WELL TOLERATED THROUGHOUT STUDY

* CAPRICOR THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.30 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below